When we launched, Medly was simply a telehealth provider aiming to radically improve the affordability and accessibility of healthcare to Australians.
Today, Medly’s intake system was included on the Australian Register of Therapeutic Goods (ARTG) as a Class I Software as a Medical Device (SaMD), under the oversight of the Therapeutic Goods Administration.
I think this milestone matters less for what it says about Medly today, and more for what it signals about where digital health is going.
Most healthcare inefficiency sits upstream of the doctor. Variability in how patient histories are captured leads to longer consults, fragmented documentation, and inconsistent outcomes.
Medly was built to address that layer.
It structures a patient’s history before the consult begins, creating a consistent, clinically governed starting point for care. The system does not replace clinical judgement, but standardises how information is gathered and presented.
In beta testing, this has reduced average consult costs from ~$49 to $19 by improving efficiency at the intake stage. We’ve chosen to pass that efficiency directly to patients.
I think the more important point for the Australian healthcare industry is to consider that if software is influencing how clinical information is captured, recorded or used, it should sit within a regulatory framework, not outside it.
Being included on the ARTG is an early step in building toward that standard.
The telehealth arm of Medly is simply the environment in which we are refining the system under real-world conditions.
Longer term, the focus is on developing regulated, clinically governed infrastructure that can be embedded across healthcare settings to support clinicians at scale.
We’re already exploring how this layer can integrate with existing providers and workflows.
Read the post on LinkedIn here.